Cytiva, a global life sciences leader, will provide its FlexFactory single-use manufacturing platform to Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) for use in manufacturing mRNA vaccines.
Arranta is adding 10 million USD on top of its 100 million USD investment into its new Watertown, MA facility to open a dedicated space for mRNA manufacturing, Lipid nanoparticle (LNP) formulation, and drug product filling.
Arranta is offering the first end-to-end platform for cGMP manufacturing of mRNA products. The new space is scheduled to open within six months and will include in-vitro transcription, mRNA purification, lipid nanoparticle (LNP) formulation, and aseptic filling with first GMP production in Q3 of 2022.
Mark Bamforth, Executive chair and CEO of Arranta, noted that “Arranta is offering mRNA developers something unique: an integrated suite of complementary services from a single provider. Cytiva’s solutions provide us with the flexibility and modularity to offer our customers tailored manufacturing. With the addition of Cytiva’s robotic aseptic filling solutions, we are truly an end-to-end, single point of contact CDMO, reducing overall complexity, cost, and time to the product innovators.”
Cytiva acquired the aseptic business from Canadian company Vanrx in early 2021. The purchase completed its biomanufacturing workflow, enabling the company to offer solutions from ‘idea to injection.’
Olivier Loeillot, Vice president of Bioprocess at Cytiva, says: “Our agreement with Arranta marks the first time our full range of solutions will be used in the manufacturing of mRNA. We’ve developed our platform to work for a multitude of modalities beyond the traditional mAbs, such as cell and gene therapies, plasmid DNA, and now, mRNA. It’s exciting to support this next generation of therapies that will benefit patients globally and deliver on our company mission to advance and accelerate therapeutics.”